Table 3.
Adverse events experienced by any of the patients in this trial.
| Adverse event (AE) | All grades AEs # (%)a | Grades ≥ 3 AEs # (%) | Known AEs?b | |
|---|---|---|---|---|
| P | D | |||
| Neuropathy | 4 (29) | 0 (0) | √ | √ |
| Headache | 4 (29) | 2 (14) | √ | √ |
| Anemia | 2 (14) | 2 (14) | √ | √ |
| White blood cells decreased | 1 (7) | 1 (7) | √ | √ |
| Neutropenia | 1 (7) | 1 (7) | √ | |
| Eosinophilia | 1 (7) | 0 (0) | √ | √ |
| Fatigue | 3 (21) | 1 (7) | √ | √ |
| Fever | 1 (7) | 0 (0) | √ | √ |
| Sore throat | 1 (7) | 0 (0) | √ | √ |
| Edema | 1 (7) | 0 (0) | √ | √ |
| Diarrhea | 2 (14) | 0 (0) | √ | √ |
| Constipation | 1 (7) | 0 (0) | √ | √ |
| Colitis | 1 (7) | 0 (0) | √ | √ |
| Increased ALT/AST enzymes | 1 (7) | 0 (0) | √ | |
| Dyspnea | 1 (7) | 0 (0) | √ | |
| Cough | 1 (7) | 0 (0) | √ | |
| Skin rash | 3 (21) | 1 (7) | √ | √ |
| Pruritus | 2 (14) | 0 (0) | √ | |
| Vaginal dryness | 1 (7) | 0 (0) | √ | |
| Alopecia | 2 (14) | 0 (0) | √ | √ |
| Nail infection | 1 (7) | 0 (0) | √ | |
| Nail changes | 1 (7) | 0 (0) | √ | |
| Palpitation | 2 (14) | 0 (0) | √ | |
| Wt. gain | 2 (14) | 0 (0) | √ | |
| Hoarseness of voice | 1 (7) | 0 (0) | √ | √ |
| Hypophysitis | 1 (7) | 0 (0) | √ | |
| High cholesterol | 1 (7) | 0 (0) | √ | |
| Myalgia | 1 (7) | 0 (0) | √ | √ |
| Arthralgia | 1 (7) | 0 (0) | √ | √ |
| Back pain | 1 (7) | 0 (0) | √ | |
| Dry eye | 1 (7) | 0 (0) | √ | |
a% from total of 14 patients. Of note, the two patients who received one dose of Durvalumab only did not report any AEs
bKnown AE from drug brochure for either Paclitaxel (P) or Durvalumab (D) or both. Bold AEs are well-known or common (> 10% of patients had experienced it in previous monotherapy trials).